News & Updates
Filter by Specialty:
Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC
An updated analysis of MARIPOSA reveals significant reductions in the incidence of MET and EGFR resistance alterations with first-line amivantamab plus lazertinib compared with osimertinib, with no upregulation in other resistance pathways, in patients with nonsmall cell lung cancer (NSCLC).
Amivantamab-lazertinib combo improves survival by reducing resistance mechanisms in NSCLC
05 Nov 2025
SGLT-2i lowers autoimmune rheumatic disease risk in T2D
The use of sodium-glucose cotransporter-2 (SGLT-2) inhibitors, compared with sulfonylureas, results in a reduced risk of autoimmune rheumatic disease among adults with type 2 diabetes (T2D), reports a recent study.
SGLT-2i lowers autoimmune rheumatic disease risk in T2D
04 Nov 2025
Dual RF, ACPA positivity linked to RA manifestations
Patients with rheumatoid arthritis (RA) who are positive for both anticyclic citrullinated peptide antibody (ACPA) and rheumatoid factor (RF) have lower remission rate, higher baseline erythrocyte sedimentation rate (ESR), and need more corticosteroid and disease-modifying antirheumatic drugs (DMARDs) than those with single positivity or double negativity, according to a Singapore study.